Astria Therapeutics, Inc.
DelistedCIK 1454789fmd_027TNKK09X5MBHBR9EHWSVT1Z9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2025, 48 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 1 | 0 | – | 0 | – | – | – | – |
| Research and development | 23 | 25 | 19 | 17 | 18 | 26 | 16 | 34 | 42 | 77 |
| Total operating expenses | 32 | 36 | 28 | 26 | 27 | 37 | 195 | 54 | 83 | 112 |
| Operating income | (32) | (36) | (27) | (26) | (27) | (37) | (195) | (54) | (83) | (112) |
| Interest expense | 1 | 1 | 0 | 0 | – | – | – | – | – | – |
| Interest and investment income | – | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 10 | 17 |
| Other non-operating income (expense) | (1) | (1) | (0) | 1 | 1 | 0 | 0 | 2 | 10 | 17 |
| Net income | (33) | (36) | (27) | (26) | (26) | (37) | (195) | (52) | (73) | (94) |
| Net income to common shareholders | – | – | – | – | – | (37) | (219) | (52) | – | – |